Myelodysplastic syndromes
Also known as: Myelodysplastic neoplasms, MDS, Myelodysplasia, Myelodysplastic disorders
Myelodysplastic syndromes (MDS) comprise clonal myeloid malignancies characterised by ineffective haematopoiesis, resulting in peripheral cytopenias and variable risk of transformation to acute myeloid leukaemia. Management is contingent upon haematologist-led risk stratification and clinical intervention. Although TCM assessment provides a traditional framework for discussing symptoms such as fatigue, appetite, or sleep, these presentations must not be interpreted independently of haematological parameters or treatment-related toxicities. The cited evidence includes laboratory-based molecular research and exploratory diagnostic signatures; it provides no clinical validation for the efficacy of acupuncture or the specified herbal formulas in improving MDS outcomes. Adjunctive interventions require prior authorisation from the treating haematologist and must not impede blood transfusions, pharmacological therapies, haematopoietic stem cell transplantation assessments, or urgent diagnostic investigations.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Calibrate gentle physical activity with structured rest periods, adhering to haematological guidelines regarding anaemia-related syncope and fall risks.
- •Maintain consistent nutritional intake and monitor body mass; consult a clinical dietitian for reduced oral intake rather than initiating unvalidated supplementation.
- •Adhere strictly to hand hygiene protocols, food safety guidance, and advice on avoiding infection exposure as directed by the haematology team.
- •Maintain records of symptoms, body temperature, and medications, and ensure attendance at all scheduled pathology assessments and haematology reviews.
Cautions & Contraindications
- •Defer needling with fever, suspected infection, active bleeding or clinically significant cytopenias until the haematology team confirms suitability using current counts and clinical status. This is a precautionary clinical recommendation; the cited MDS study does not establish needling thresholds.[]
- •Do not translate the Qinghuang powder cell-culture findings into a recommendation for arsenic-containing preparations. The supplied study reports laboratory effects, not clinical efficacy, safe dosing or patient-level safety; the corrigendum abstract provides no correction details.[,]
- •Do not replace prescribed MDS treatment with any listed formula or use molecular findings to select unapproved therapy. The supplied mechanistic and candidate-signature studies do not establish efficacy or interaction safety for these formulas.[,,]
When to reassess or seek care again
Before any intervention, document haematology agreement, current blood counts, bleeding and infection history, medicines and patient priorities. If adjunctive care is approved, review within 1–2 weeks using fatigue and sleep scores from 0–10, appetite, weight, stool frequency and adverse effects. Blood-count and transfusion monitoring remain haematology-led and must not be attributed to TCM. Stop and refer immediately for red flags; reconsider or discontinue after 2–4 weeks without meaningful symptom benefit.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Journal of ethnopharmacology · 2027
- Journal of ethnopharmacology · 2026
- Neoplasma · 2026
- Hematology (Amsterdam, Netherlands) · 2026
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
